BIRC5 and neoplasm: Anti-tumor cellular immune responses may be directed against: (i) non-mutant but overexpressed targets i.e. mesothelin, NY-ESO-1, survivin, (ii) private mutated proteins (neoantigens) as well as (iii) mutant targets that are shared among different individuals (shared neoantigen), such as KRAS (39).